Symbols

NVRO(Delisted)

Nevro·NYSE

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NVRO

Nevro Corp.

A company that develops a spinal cord stimulation system for the treatment of chronic leg and back pain

Industry

Established Date

03/10/2006

Listing Date

11/06/2014

Exchange

New York Stock Exchange

Full-time Employees

1,099

Fiscal Year Ends

12-31

Website

www.nevro.com

Security Type

Common stock

Office address

1800 Bridge Parkway, Redwood City, California 94065

Business

Introduction

Nevro Corp., incorporated in Minnesota on March 10, 2006, manufactures and promotes innovative active implantable medical devices for the treatment of neurological disorders with an initial focus on the treatment of chronic pain. The company, a medical device company, has developed and commercialized an innovative neuromodulation platform for the treatment of chronic pain.

Company Financials

EPS

NVRO has released its 2024 Q4 earnings. EPS was reported at -0.39, versus the expected -0.75, beating expectations. The chart below visualizes how NVRO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NVRO has released its 2024 Q4 earnings report, with revenue of 105.55M, reflecting a YoY change of -9.15%, and net profit of -53.11M, showing a YoY change of -491.37%. The Sankey diagram below clearly presents NVRO's revenue sources and cost distribution.